Amgen's Blincyto puts leukemia patients in remission; Biogen confirms second PML case in Tecfidera patients;

> In a Phase II study, a "clinically meaningful" number of relapsed or refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (ALL) patients taking Amgen's ($AMGN) Blincyto experienced complete remission or complete remission with partial hematological recovery. Release | Story

> Biogen ($BIIB) has confirmed the second case of rare brain disease progressive multifocal leukoencephalopathy (PML) among Tecfidera patients. More

> AstraZeneca ($AZN) has entered an agreement with Kyowa Hakko Kirin for an exclusive option to market current candidate drug benralizumab for asthma and COPD in Japan. Release

> Germany's price watchdog has reassessed the data on Novartis' ($NVS) MS pill Gilenya, and it's now recommending the treatment for more patients. Report

And Finally... Scientists believe they can use smartphones to identify people suffering depressive symptoms with 87% accuracy. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

The Tecentriq-Avastin-chemo cocktail did slightly better in PD-L1-positive patients but still failed to cross the statistical significance bar.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.